Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
Christoph Funke's extensive career includes leadership roles at organizations such as Fresenius Kabi and Strides Pharma Science
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
ANVISA issues CGMP to Concord Biotech’s Unit I
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
The said Unit complies with the prescribed Good Manufacturing practices as per relevant WHO technical Report Series
The agreement sets terms under which POC will manufacture the product or receive royalties
Subscribe To Our Newsletter & Stay Updated
